Skip to content
lifestyle.brickvest.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Immix Biopharma, Inc.
Immix Biopharma Announces Closing of $150 Million Underwritten Offering of Common Stock
May 27, 2026
Immix Biopharma Announces Pricing of $150 Million Underwritten Offering of Common Stock
May 27, 2026
Immix Biopharma Announces 95% Complete Response Rate in Interim Update From relapsed/refractory AL Amyloidosis Clinical Trial NEXICART-2
May 27, 2026
Immix Biopharma to Participate in the Jefferies Global Healthcare Conference
May 21, 2026
Immix Biopharma Announces Enrollment Completion of BLA-Enabling Relapsed/Refractory AL Amyloidosis Trial NEXICART-2, and Upcoming Milestones
May 19, 2026
Immix Biopharma Receives U.S. FDA Breakthrough Therapy Designation for NXC-201
January 28, 2026